Niki BioSolutions, Inc 6-K, filed May 31, 2022
Niki BioSolutions, Inc. (NIKI)
About this 6-K
Niki BioSolutions, Inc filed this 6-K on May 31, 2022.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of May 2022
Commission File Number: 001-38764
APTORUM GROUP LIMITED
17 Hanover Square
London W1S 1BN, United Kingdom
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Mr. Darren Lui, Aptorum Group Limited’s (the “Company”) President and Executive Director, has been appointed Chief Executive Officer (“CEO”), effective June 1, 2022. Mr. Lui succeeds Mr. Ian Huen, who will be stepping down as Chief Executive Officer, but will remain on the Company’s board as a non-executive director on the same effective date.
Mr. Lui’s appointment comes as part of the Company’s continued focus on the development and discovery of its therapeutics and diagnostics products. Under Mr. Huen and Mr. Lui’s stewardship, the Company has successfully brought two small molecule drugs (ALS-4 and SACT-1) from discovery to their respective completion of two phase I clinical trials and currently in preparation for their next phase of clinical trials in human patients, as well as conducting ongoing clinical validations of the Company’s RPIDD program, a liquid biopsy based molecular diagnostics for infectious diseases. The Board is very pleased to be able to appoint Mr. Lui as the Company’s new CEO. Mr. Lui’s compensation will not change as a result of the appointment. Mr. Lui has great understanding of the Company’s current and ongoing operations and his appointment as CEO ensures continuity in the Company’s leadership going forward.
Mr. Huen’s resignation is part of an organized and transparent succession plan, in benefit of all shareholders and stakeholders of the Company.
The information in this Form 6-K, including the exhibits shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
This Form 6-K is hereby incorporated by reference into the registration statements of the Company on Form S-8 (Registration Number 333-232591) and Form F-3 (Registration Number 333-235819) and into each prospectus outstanding under the foregoing registration statements, to the extent not superseded by documents or reports subsequently filed or furnished by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Aptorum Group Limited | |||
| Date: May 31, 2022 | By: | /s/ Sabrina Khan | |
| Name: | Sabrina Khan | ||
| Title: | Chief Financial Officer | ||